These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18501093)

  • 1. Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.
    Dziadziuszko R; Hirsch FR
    Clin Lung Cancer; 2008 Mar; 9(2):78-84. PubMed ID: 18501093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
    Gray J; Simon G; Bepler G
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of biomarkers in advanced non-small-cell lung cancer.
    Socinski MA
    Clin Lung Cancer; 2010 May; 11(3):149-59. PubMed ID: 20439190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological markers in lung cancer: A clinician's perspective.
    Tufman A; Huber RM
    Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biologic staging of lung cancer.
    D'Amico TA
    Ann Thorac Surg; 2008 Feb; 85(2):S737-42. PubMed ID: 18222207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational research in lung cancer.
    Chen Y; Okunieff P; Ahrendt SA
    Semin Surg Oncol; 2003; 21(3):205-19. PubMed ID: 14508854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of non-small-cell lung cancer.
    Lacroix L; Commo F; Soria JC
    Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
    Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
    Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGF receptor in lung cancer: a successful story of targeted therapy.
    Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
    Sriram KB; Larsen JE; Yang IA; Bowman RV; Fong KM
    Respirology; 2011 Feb; 16(2):257-63. PubMed ID: 21044232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biology of epidermal growth factor receptor in lung cancer.
    Scagliotti GV; Selvaggi G; Novello S; Hirsch FR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4227s-4232s. PubMed ID: 15217963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of targeted therapy in non-small cell lung cancer.
    Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.